Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01456936 · ClinicalTrials.gov registry record · Phase 4
Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 8,144
- Enrollment target
NCT01456936 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 8,144 participants.
The verdict
NCT01456936, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8,144 participants
- Enrollment target
Study Summary
This study is being conducted to assess varenicline and bupropion as aids to smoking cessation treatment in subjects with and without an established diagnosis of major psychiatric disorder and to characterize the neuropsychiatric safety profile (pre-specified adverse events (AEs) in both of these populations).
Interventions
- DRUG Placebo
- DRUG Nicotine Replacement Therapy Patch
- DRUG bupropion hydrochloride
- DRUG varenicline tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,144 participants |
| Start Date | 2011-11 |
| Est. Completion | 2015-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01456936
The ClinicalTrials.gov registry entry for NCT01456936 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 8,144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01456936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01456936 about?
NCT01456936 is a clinical study titled "Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders". This study is being conducted to assess varenicline and bupropion as aids to smoking cessation treatment in subjects with and without an established diagnosis of major psychiatric disorder and to characterize the neuropsychiatric safety profile (pre-specified adverse events (AEs) in both of these po...
What is the current status of trial NCT01456936?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8,144 participants. The study started on 2011-11. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01456936?
The interventions under investigation include: Placebo (DRUG), Nicotine Replacement Therapy Patch (DRUG), bupropion hydrochloride (DRUG), varenicline tartrate (DRUG).
Who is sponsoring clinical trial NCT01456936?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.